🔥 This is a sponsored post. For more information, please visit this page.
CBD oil has been praised as the remedy to many of the most prevalent ills facing people today, from anxiety to osteoarthritis. Early clinical studies have shown promise, but the bulk of the sentiment is based on anecdotal evidence converging with a desire for more holistic treatments outside the scope of potent pharmaceutical drugs.
As a result, the CBD market, and the growing phenomenon of CBD oil treatments have tended to promote everything from tinctures to sports drinks and other CBD-infused products based on misconstrued information. When effective dosages of CBD treatment are still under medical exploration, it is challenging to find a sliver of clinically-backed data on the positive use of CBD.
And that’s the area where Viridian Pharmaceuticals thinks they can have a lasting impact — fusing holistic, topical treatment of clinically-driven CBD products.
Relying on natural therapeutic delivery that is based on the firm’s extensive clinical research in skin-based bio-delivery, Viridian is at the cutting edge of what the CBD market hopefully transforms into for it to become more widely accepted in the medical community.
The Need for a Clinical Roadmap
The anecdotal evidence of CBD oils and other CBD-infused treatments range from solutions to arthritis, anxiety, sleep disorders, schizophrenia, and much more. However, like past “panacea treatments,” much of the hype surrounding CBD should be taken with a grain of salt — a notion reflected by medical professionals and the FDA as the market matures.
“We need to be focused on moving the needle on the science of CBD with a clinical path aimed to demonstrate that CBD combined with our penetration technology can be applied on the skin and have therapeutic benefit, positively impacting a variety of indications,” says Layne Beal, CEO of Viridian.
Current clinical roadmaps are only in their early stages and backed by some clinical evidence that has begun coming out of some labs. For example, formal clinical studies have linked reduced instances of seizures to CBD treatments in people with epilepsy, and CBD has been cited as a promising pathway for alleviating symptoms of multiple sclerosis.
The problem is that these are still nascent developments, and much more exploration, along with mature clinical roadmaps, are necessary to push the needle forward like Beal mentions.
“With the increasing clarity around the legal status of hemp-derivatives, including cannabidiol (CBD), we have a strong clinical path to investigate how delivering the CBD molecule via our cream-based carrier can help specific indications, and the current pipeline includes chronic migraines and osteoarthritis,” details Beal.
Viridian’s plan is also intriguing for another reason: the actual delivery pathway of CBD is predicated on their history of biopharma drug delivery, R&D, and clinical studies, where topical cream treatments can deliver molecules to areas previously matched only by IVs.
Such developments are critical, largely because of the lack of standardized dosage indicators for CBD treatments, with tinctures ranging vastly in delivered milligrams of CBD and many dispensary-driven packaging misleading consumers on the health impact.
Natural, Therapeutic Delivery for Proven Results
Viridian’s CBD topical cream product is called Notion, and they have several others in the pipeline that are going through their formal clinical roadmap.
For consumers, the accessibility of more accurate information concerning CBD products is vital, as many observers see producers taking advantage of the tremendous rise in demand of CBD in a “snake oil salesmen” type of manner. For their part, Viridian views the ongoing developments as an opportunity to showcase the tangible, clinically-driven results of CBD topical treatments — removing many of the misconceptions in the process.
“Our current clinical roadmap includes migraines and osteoarthritis,” says Beal. “And as far as Notion goes, we have evaluated the efficacy of our product through pharmacokinetic studies and bioavailability analysis, comparing the results with other publicly available studies.”
Viridian has subsequently been able to show that their product can deliver more CBD into the system more quickly, and for a more sustained period of time than other routes of delivery. As a result, Viridian’s Notion is an ideal solution for patients suffering from the conditions targeted by Viridian that are also looking for holistic treatment options as simple as a topical cream — rather than misleading products available in e-commerce stores with arbitrary dosage amounts.
“We believe in commercializing only the best products and have spent the last year performing in-home trials of our iterative formulations to deliver the best consumer experience,” says Beal.
Those trials shaped Notion, and consistently positive feedback from the testimonials is what may ultimately push the needle where it needs to go concerning clinically-driven CBD adoption.
Where there is continual hype around CBD products, there’s a lot of misinformation. Foods infused with CBD and tinctures distributed by marijuana dispensaries with arbitrary doses are not the optimal path towards clinical acceptance of the promising cannabinoid. Viridian’s push for a clinically-driven roadmap of a natural, therapeutic delivery mechanism is a microcosm for the broader endeavors of the medical community to explore the benefits of CBD, and could be the pivotal area where CBD can make a tangible clinical impact across a variety of ailments.